CD63 and neoplasm: More recently, Aaberg-Jessen et al. (2018) demonstrated that Co-expression of TIMP-1 and CD63 might have effects in glioblastoma stemness and may predict the poor prognosis of patients through influencing tumor aggressiveness and resistance of therapy.